Radiopharm Theranostics Limited (RADX)

NASDAQ: RADX · Real-Time Price · USD
5.30
+0.13 (2.42%)
Aug 19, 2025, 3:08 PM - Market open
2.42%
Market Cap38.35M
Revenue (ttm)204,609
Net Income (ttm)-26.61M
Shares Out 2.20B
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,807
Open5.08
Previous Close5.18
Day's Range4.80 - 5.50
52-Week Range3.50 - 50.82
Beta0.80
AnalystsStrong Buy
Price Target15.00 (+183.02%)
Earnings DateFeb 26, 2025

About RADX

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Australia
Stock Exchange NASDAQ
Ticker Symbol RADX
Full Company Profile

Financial Performance

In 2024, Radiopharm Theranostics's revenue was 1.96 million, a decrease of -68.46% compared to the previous year's 6.21 million. Losses were -47.95 million, 38.5% more than in 2023.

Financial numbers in AUD Financial Statements

Analyst Summary

According to 3 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 183.02% from the latest price.

Price Target
$15.0
(183.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

There is no news available yet.